Merck: encouraging Phase 3 results in esophageal carcinoma
(CercleFinance.com) - Merck said a Phase 3 trial investigating Keytruda in advanced esophageal or esophagogastric junction carcinoma has met a primary endpoint of overall survival.
In this pivotal study, the therapy, which increases the ability of the body's immune system to help fight tumor cells, resulted in a statistically significant improvement in overall survival compared to chemotherapy in patients whose tumors expressed PD-L1.
In a statement, Merck said it was "encouraged" by these results.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In this pivotal study, the therapy, which increases the ability of the body's immune system to help fight tumor cells, resulted in a statistically significant improvement in overall survival compared to chemotherapy in patients whose tumors expressed PD-L1.
In a statement, Merck said it was "encouraged" by these results.
Copyright (c) 2018 CercleFinance.com. All rights reserved.